Trial Profile
A Multicenter, Randomized, Controlled, Phase III Trial Comparing High-Dose IFN-a2b With Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Aug 2022
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Temozolomide (Primary) ; Interferon
- Indications Gastrointestinal cancer; Gynaecological cancer; Head and neck cancer; Malignant melanoma
- Focus Therapeutic Use
- 07 Jun 2022 Status changed to completed , according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Primary endpoint has been met (Relapse-free survival of high-dose IFN-a2b and temozolomide-based chemotherapy as adjuvant therapy for resected mucosal melanoma) , according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology